4DMedical Invests in RevealDx, Forges Distribution Agreement

4DMedical has forged a distribution agreement with and made a $3.4 million strategic investment in RevealDx, developer of an artificial intelligence (AI)-enabled method for characterizing lung nodules. The agreement and financing expands access to RevealDx’s flagship product, RevealAI-Lung, which has is authorized for sale in Europe, Australia, and the United States.

The partnership follows 4DMedical’s recent acquisition of Austrian-based contextflow, which offers advanced chest CT technologies that automate the identification of lung nodules. 4DMedical is aiming to revolutionize respiratory care through advanced imaging and AI. RevealAI-Lung has been integrated into the contextflow platform and is already operational at several clinical sites in Europe.

“We are excited to announce our new partnership with 4DMedical,” RevealDx CEO Chris Wood said. “… this milestone underscores our commitment to helping clinicians identify potentially malignant lung nodules earlier and with greater confidence. The team at 4DMedical and the resources they bring will expand our reach and benefit patients.”

The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI), a score that helps radiologists make more informed follow-up recommendations to assist in cancer diagnosis. The company has validated the software on more than 1,500 patients from various cohorts.

The RevealAI-Lung CADx device offers several key capabilities, including:

• Significant improvement in radiologist reader performance
• Use of real world NLST data as a reference population
• Clinically relevant malignancy scoring 
• First ever integration directly into PACS, vastly improving workflow
• Proven generalizability across exam types and patient populations

“For 4DMedical, this is about more than adding products. It is about building a connected ecosystem for cardiopulmonary care. CT:VQ gives physicians physiological insight into how the lung is actually functioning,” 4DMedical Founder/CEO Andreas Fouras stated. “By surrounding that capability with disease detection and AI-powered risk stratification, we can help health systems identify the right patients earlier and ensure they receive appropriate care. The result is a platform that has the potential to improve outcomes for patients while increasing utilization of advanced functional imaging across vital disease areas.”

In addition to its recent regulatory milestones, RevealAI-Lung is reimbursable by Medicare in the United States under CPT codes 0721T and 0722T, helping to support broader clinical adoption.

RevealDx has developed RevealAI-Lung, the first medical imaging AI software to achieve reimbursement in both the United States and European Union. The company has published several studies demonstrating significant improvement in both early cancer detection and reduction in false positives. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. 

4DMedical Limited is a global medical technology company developing respiratory care solutions through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard scans into functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision. 4DMedical’s expanding software portfolio includes the U.S. Food and Drug Administration-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS, and the CT:VQ solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis. 

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical’s solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of Imbio and 2026 purchase of contextflow, 4DMedical is pushing the boundaries of medical imaging to redefine the way respiratory disease is understood and treated worldwide.